A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs COH 29 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 27 Jun 2016 New source identified and integrated (NCT02112565).
- 23 Jun 2016 Status changed from planning to recruiting, as reported in a Novonco Therapeutics media release.